NCT04292535 - Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

February 20, 2020

Conditions

InsulinExercise

Interventions

DRUG

Placebo into the intranasal mucosa

6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer

DRUG

20 IU NovoLog Insulin aspart into the intranasal mucosa

5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

DRUG

40 IU NovoLog Insulin aspart into the intranasal mucosa

4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

DRUG

60 IU NovoLog Insulin aspart into the intranasal mucosa

3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

DRUG

80 IU NovoLog Insulin aspart into the intranasal mucosa

2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

DRUG

100 IU NovoLog Insulin aspart into the intranasal mucosa

1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

DRUG

120 IU NovoLog Insulin aspart into the intranasal mucosa

6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Trial Locations (1)

48824

Department of Kinesiology, East Lansing

All Listed Sponsors

lead

Michigan State University

OTHER